China Pharma Holdings Stock Beta
| CPHI Stock | USD 0.20 0.01 5.26% |
China Pharma Holdings fundamentals help investors to digest information that contributes to China Pharma's financial success or failures. It also enables traders to predict the movement of China Stock. The fundamental analysis module provides a way to measure China Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to China Pharma stock.
China | Beta |
China Pharma Holdings Company Beta Analysis
China Pharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current China Pharma Beta | 0.71 |
Most of China Pharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China Pharma Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
China Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for China Pharma is extremely important. It helps to project a fair market value of China Stock properly, considering its historical fundamentals such as Beta. Since China Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of China Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of China Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, China Pharma Holdings has a Beta of 0.711. This is 17.33% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
China Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China Pharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of China Pharma could also be used in its relative valuation, which is a method of valuing China Pharma by comparing valuation metrics of similar companies.China Pharma is currently under evaluation in beta category among its peers.
China Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of China Pharma from analyzing China Pharma's financial statements. These drivers represent accounts that assess China Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of China Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 51.6M | 97.2M | 111.3M | 2.0M | 2.4M | 2.2M | |
| Enterprise Value | 55.1M | 103.7M | 118.9M | 5.3M | 6.0M | 5.7M |
As returns on the market increase, China Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding China Pharma is expected to be smaller as well.
China Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (1.50) % | ||||
| Current Valuation | 8.8 M | ||||
| Shares Outstanding | 19.25 M | ||||
| Shares Owned By Insiders | 51.27 % | ||||
| Shares Owned By Institutions | 0.21 % | ||||
| Number Of Shares Shorted | 93.6 K | ||||
| Price To Earning | (0.89) X | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 7.01 M | ||||
| Gross Profit | 349.27 K | ||||
| EBITDA | 8.44 K | ||||
| Net Income | (3.08 M) | ||||
| Cash And Equivalents | 2.24 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 4.63 M | ||||
| Debt To Equity | 2.62 % | ||||
| Current Ratio | 0.75 X | ||||
| Book Value Per Share | 0.70 X | ||||
| Cash Flow From Operations | (699.69 K) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (0.69) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 231 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 3.69 M | ||||
| Total Asset | 16.47 M | ||||
| Retained Earnings | (39.29 M) | ||||
| Working Capital | (823.73 K) | ||||
| Current Asset | 20.99 M | ||||
| Current Liabilities | 12.95 M | ||||
| Net Asset | 16.47 M |
About China Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China Pharma Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Pharma Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out China Pharma Piotroski F Score and China Pharma Altman Z Score analysis. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.